Report : North America Human Papillomavirus (HPV) Vaccine Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (9-Valent HPV Vaccine, Quadrivalent HPV Vaccine, and Bivalent HPV Vaccine), Dosage (2 Dose and 3 Dose), Age (9 to 14 Years and 15 to 45 Years), Application (HPV-Attributable Cancer and Genital Warts), and End User (Doctors Office, Community Health Clinics, School-Based Health Centers, Health Departments, Hospitals, and Others)
At 4.7% CAGR, the North America Human Papillomavirus (HPV) Vaccine Market is speculated to be worth US$ 2,964.96 million by 2028, says The Insight Partners
According to Business Market Insights’ research, the North America human papillomavirus (HPV) vaccine market was valued at US$ 2,247.18 million in 2022 and is expected to reach US$ 2,964.96 million by 2028, registering an annual growth rate of 4.7% from 2022 to 2028. Increase in prevalence of HPV associated diseases and growing number of hpv awareness programs are the critical factors attributed to the market expansion.
Human papillomavirus (HPV) is a common sexually transmitted infection and can cause cervical, oropharyngeal cancer, and cancer of the vagina, vulva, penis, or anus. It also causes various diseases, such as anogenital warts and recurrent respiratory papillomatosis. HPVs have also been detected in lichen sclerosus, skin tags, seborrheic keratoses, epidermal cysts, actinic keratoses, and psoriatic plaques. A significant burden of HPV-associated diseases is likely to drive the market's growth. In women, cervical cancer is the fourth most common cancer. Additionally, the American Society of Clinical Oncology (ASCO) estimated that around 14,100 cases of invasive cervical cancer would be registered in the US alone. Further, as per the report, 'Cervical cancer burden in EU-27,' in 2020, there were 30,447 new cases and 13,437 deaths due to cervical cancer in women. Further, as per the Centers for Disease Control and Prevention (CDC), in 2018, there were around 43 million HPV infections in the US. The CDC also estimated that about 19,400 women and 12,100 men annually suffer from cancers caused by HPV. Further, as per the National Foundation for Infectious Diseases (NFID), there are around 14 million new HPV infection cases in the US every year. Such a high incidence rate of HPV-associated infections is favoring the market growth.
On the contrary, high cost of HPV vaccines hurdles the growth of North America human papillomavirus (HPV) vaccine market.
Based on type, the North America human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment held 61.0% market share in 2022, amassing US$ 1,371.60 million. It is projected to garner US$ 1,805.85 million by 2028 to expand at 4.7% CAGR during 2022–2028.
Based on dosage, the North America human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment held 59.6% market share in 2022, amassing US$ 1,339.83 million. It is projected to garner US$ 1,739.07 million by 2028 to expand at 4.4% CAGR during 2022–2028.
Based on age, the North America human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment held 71.2% market share in 2022, amassing US$ 1,600.18 million. It is projected to garner US$ 2,134.50 million by 2028 to expand at 4.9% CAGR during 2022–2028.
Based on application, the North America human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment held 80.9% market share in 2022, amassing US$ 1,818.31 million. It is projected to garner US$ 2,429.30 million by 2028 to expand at 4.9% CAGR during 2022–2028.
Based on end user, the North America human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment held 42.8% market share in 2022, amassing US$ 962.16 million. It is projected to garner US$ 1,253.27 million by 2028 to expand at 4.5% CAGR during 2022–2028.
Based on country, the North America human papillomavirus (HPV) vaccine market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 87.6% market share in 2022. It was assessed at US$ 1,969.43 million in 2022 and is likely to hit US$ 2,577.14 million by 2028, exhibiting a CAGR of 4.6% during the forecast period.
Key players dominating the North America human papillomavirus (HPV) vaccine market are ChengDu Institute of Biological Products Co., Ltd.; GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; Serum Institute of India Pvt. Ltd; Vaccitech; and Walvax Biotechnology Co., Ltd. among others.
- In Nov 2021, Merck announced the successful completion of the acquisition of Acceleron Pharma Inc.
- In Feb 2021, QIAGEN and INOVIO Pharmaceuticals announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com